GlassScriptPhysician profile
Kevin J Serrano
NPI 1255962445
$14,905.40
in general payments reported to CMS, 2019-2025
33 companies · $4,162 in 2025
The $4,162 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,864 · 2022: $2,356 · 2023: $2,225 · 2024: $4,299 · 2025: $4,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $128 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,442.03 |
| Education | $128.40 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,511.68 | 2021-2025 | Azstarys |
| Abbvie INC. | $1,505.63 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,252.69 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $967.33 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $954.82 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $927.20 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $743.99 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $691.33 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $687.34 | 2022-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $686.46 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $643.28 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $629.44 | 2022-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $614.92 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $536.68 | 2021-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $415.16 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $378.48 | 2021-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $360.09 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $285.00 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $209.12 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $146.15 | 2022-2025 | Quviviq, Quviviq |
| Indivior INC. | $137.61 | 2024-2025 | Sublocade |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Spravato |
| Jazz Pharmaceuticals INC. | $96.54 | 2021-2022 | |
| Noven Therapeutics, LLC | $94.25 | 2024-2025 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $59.97 | 2024 | Rexulti |
| Owp Pharmaceuticals, INC. | $55.12 | 2021 | |
| Neuronetics, INC. | $44.35 | 2022 | |
| Adlon Therapeutics L.P. | $42.13 | 2021 | |
| Eisai INC. | $31.89 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $26.04 | 2025 | Erzofri Extended-Release |
| Alfasigma USA, INC. | $18.97 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.84 | 2024 | Relexxii |
| Novo Nordisk INC | $17.90 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.